WO2009028418A1 - シクロスポリンａ結合タンパク質 - Google Patents

シクロスポリンａ結合タンパク質 Download PDF

Info

Publication number
WO2009028418A1
WO2009028418A1 PCT/JP2008/065015 JP2008065015W WO2009028418A1 WO 2009028418 A1 WO2009028418 A1 WO 2009028418A1 JP 2008065015 W JP2008065015 W JP 2008065015W WO 2009028418 A1 WO2009028418 A1 WO 2009028418A1
Authority
WO
WIPO (PCT)
Prior art keywords
csabp
binding protein
cyclosporin
promoter
targets
Prior art date
Application number
PCT/JP2008/065015
Other languages
English (en)
French (fr)
Inventor
Hiroeki Sahara
Yoko Mori
Nobuaki Takahashi
Noriyuki Sato
Fumio Sugawara
Kengo Sakaguchi
Kengo Morohashi
Kazuki Iwabata
Koichi Watashi
Kunitada Shimotohno
Kokichi Kikuchi
Wataru Tsutae
Hiroki Miyashita
Original Assignee
Sapporo Medical University
Tokyo University Of Science
Kyoto University
Sapporo Immuno Diagnostic Laboratory
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sapporo Medical University, Tokyo University Of Science, Kyoto University, Sapporo Immuno Diagnostic Laboratory filed Critical Sapporo Medical University
Priority to US12/674,969 priority Critical patent/US20110158908A1/en
Priority to JP2009530084A priority patent/JPWO2009028418A1/ja
Priority to EP08828474A priority patent/EP2193807A4/en
Publication of WO2009028418A1 publication Critical patent/WO2009028418A1/ja

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
    • G01N33/5767—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis non-A, non-B hepatitis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)

Abstract

　本発明は、シクロスポリンＡ結合タンパク質（ＣＳＡＢＰ）を標的とした、ＣＳＡＢＰ関連疾患の診断および／または処置、ＲＮＡウイルスの増殖の制御、およびＲＮＡ代謝系の制御のための組成物および方法、ＣＳＡＢＰを標的とする成分のスクリーニング方法、ＣＳＡＢＰを利用した、ＣｓＡ、ＮＳ５ＢまたはシクロフィリンＢの検出・阻害のための組成物および方法、ならびに、ＣＳＡＢＰのプロモーター、これを利用したＣＳＡＢＰの発現を制御する物質のスクリーニング方法、およびＣＳＡＢＰ関連疾患の発症または病期を判定する方法に関する。
PCT/JP2008/065015 2007-08-24 2008-08-22 シクロスポリンａ結合タンパク質 WO2009028418A1 (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US12/674,969 US20110158908A1 (en) 2007-08-24 2008-08-22 Cyclosporin a-binding protein
JP2009530084A JPWO2009028418A1 (ja) 2007-08-24 2008-08-22 シクロスポリンａ結合タンパク質
EP08828474A EP2193807A4 (en) 2007-08-24 2008-08-22 BINDING PROTEIN AT CYCLOSPORIN A

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007217755 2007-08-24
JP2007-217755 2007-08-24

Publications (1)

Publication Number Publication Date
WO2009028418A1 true WO2009028418A1 (ja) 2009-03-05

Family

ID=40387140

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/065015 WO2009028418A1 (ja) 2007-08-24 2008-08-22 シクロスポリンａ結合タンパク質

Country Status (4)

Country Link
US (1) US20110158908A1 (ja)
EP (1) EP2193807A4 (ja)
JP (1) JPWO2009028418A1 (ja)
WO (1) WO2009028418A1 (ja)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013054846A1 (ja) * 2011-10-11 2013-04-18 日清食品ホールディングス株式会社 哺乳動物細胞を用いた変異原性試験法
JP2017046716A (ja) * 2009-07-31 2017-03-09 クロモセル コーポレーション 細胞運命の修飾因子を同定および検証するための方法および組成物

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10259182A (ja) 1997-01-14 1998-09-29 Snow Brand Milk Prod Co Ltd 新規ベンゾフラノン誘導体及びその製造方法
JP2003219893A (ja) 2001-11-21 2003-08-05 Mitsubishi Chemicals Corp 遺伝子発現阻害方法
WO2006068232A1 (ja) 2004-12-22 2006-06-29 Sapporo Medical University 線維化抑制のための薬物担体および薬物担体キット
JP2007015926A (ja) 2003-10-06 2007-01-25 Fujisawa Pharmaceut Co Ltd Ｃ型肝炎治療剤
JP2007504260A (ja) 2003-09-03 2007-03-01 ノバルティス アクチエンゲゼルシャフト Ｈｃｖ障害の処置のための修飾シクロスポリンの使用
JP2007505114A (ja) 2003-09-11 2007-03-08 ブリストル−マイヤーズ スクイブ カンパニー Ｃ型肝炎ウイルスを治療するためのシクロアルキル複素環化合物

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10259182A (ja) 1997-01-14 1998-09-29 Snow Brand Milk Prod Co Ltd 新規ベンゾフラノン誘導体及びその製造方法
JP2003219893A (ja) 2001-11-21 2003-08-05 Mitsubishi Chemicals Corp 遺伝子発現阻害方法
JP2007504260A (ja) 2003-09-03 2007-03-01 ノバルティス アクチエンゲゼルシャフト Ｈｃｖ障害の処置のための修飾シクロスポリンの使用
JP2007505114A (ja) 2003-09-11 2007-03-08 ブリストル−マイヤーズ スクイブ カンパニー Ｃ型肝炎ウイルスを治療するためのシクロアルキル複素環化合物
JP2007015926A (ja) 2003-10-06 2007-01-25 Fujisawa Pharmaceut Co Ltd Ｃ型肝炎治療剤
WO2006068232A1 (ja) 2004-12-22 2006-06-29 Sapporo Medical University 線維化抑制のための薬物担体および薬物担体キット

Non-Patent Citations (27)

* Cited by examiner, † Cited by third party
Title
"Hyoujun Yakuzaigaku' (Standard Pharmaceutics)", 2003
AHN S. ET AL., MOL CELL BIOL, vol. 18, 1998, pages 967 - 977
AUSUBEL ET AL.: "Current Protocols in Molecular Biology", 1992, GREENE PUBLISHING ASSOCIATES
BERNSTEIN BE ET AL., CELL, vol. 128, no. 4, 2007, pages 669 - 81
BOST AG ET AL., J VIROL., vol. 77, no. 7, 2003, pages 4401 - 8
CUI X ET AL., HUM PATHOL., vol. 37, no. 3, 2006, pages 298 - 311
FLORIN EL ET AL., SCIENCE, vol. 264, no. 5157, 1994, pages 415 - 7
FRESE M ET AL., HEPATOLOGY, vol. 35, no. 3, 2002, pages 694 - 703
GONZALEZ, G. A.; MONTMINY, M. R., CELL, vol. 59, 1989, pages 675 - 680
GONZALEZ-AMARO R ET AL., J EXP MED, vol. 179, no. 3, 1994, pages 841 - 848
HWANG DR ET AL., ANTIMICROB AGENTS CHEMOTHER., vol. 48, no. 8, 2004, pages 2876 - 82
LOHMANN V, SCIENCE, vol. 285, no. 5424, 1999, pages 110 - 3
MIYANARI Y ET AL., J BIOL CHEM., vol. 278, no. 50, 12 December 2003 (2003-12-12), pages 50301 - 8
MURATA T ET AL., VIROLOGY, vol. 331, no. 2, 2005, pages 407 - 17
NAKAGAWA M ET AL., BIOCHEM, vol. 313, no. 1, 2004, pages 42 - 7
NGUYEN, L. Q. ET AL., MOL. ENDOCRINOL., vol. 14, 2000, pages 1448 - 1461
OKANAMI ET AL., NUCLEIC ACIDS RES, vol. 26, 1998, pages 2638 - 2643
REUSCH, J. E. ET AL., MOL. CELL. BIOL., vol. 20, 2000, pages 1008 - 1020
SAMBROOK ET AL.: "Molecular Cloning: A Laboratory Manual", 2001, SPRING HARBOR PRESS
See also references of EP2193807A4 *
TILG H ET AL., GASTROENTEROL, vol. 103, no. 1, 1992, pages 264 - 274
WATASHI K ET AL., CELL, vol. 19, no. 1, 2005, pages 111 - 22
WATASHI K ET AL., HEPATOLOGY, vol. 38, no. 5, 2003, pages 1282 - 8
WATASHI K ET AL.: "Cyclophilin B is a functional regulator of hepatitis C virus RNA polymerase", MOL CELL, vol. 19, no. 1, July 2005 (2005-07-01), pages 111 - 122, XP002999378 *
WU JZ ET AL.: "Targeting NS5B RNA-dependent RNA polymerase for anti-HCV chemotherapy", CURRENT DRUG TARGETS. INFECTIOUS DISORDERS, vol. 3, no. 3, September 2003 (2003-09-01), pages 207 - 219, XP009081028 *
YE J ET AL., PROC NATL ACAD SCI U S A., vol. 100, no. 26, 2003, pages 15865 - 70
ZHU H; LIU C, J VIROL., vol. 77, no. 9, 2003, pages 5493 - 8

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017046716A (ja) * 2009-07-31 2017-03-09 クロモセル コーポレーション 細胞運命の修飾因子を同定および検証するための方法および組成物
WO2013054846A1 (ja) * 2011-10-11 2013-04-18 日清食品ホールディングス株式会社 哺乳動物細胞を用いた変異原性試験法
JPWO2013054846A1 (ja) * 2011-10-11 2015-03-30 日清食品ホールディングス株式会社 哺乳動物細胞を用いた変異原性試験法

Also Published As

Publication number Publication date
US20110158908A1 (en) 2011-06-30
JPWO2009028418A1 (ja) 2010-12-02
EP2193807A1 (en) 2010-06-09
EP2193807A4 (en) 2012-09-12

Similar Documents

Publication Publication Date Title
WO2007068985A3 (en) Diagnosis and prognosis of colorectal cancer
WO2011071574A3 (en) Monoclonal antibodies against glycoprotein of ebola sudan boniface virus
WO2006085906A3 (en) Method for the direct detection of diagnostic rna
WO2007109236A8 (en) Microrna fingerprints during human megakaryocytopoiesis
WO2007044763A3 (en) System and method for detecting fraudulent transactions
WO2008128701A3 (en) Yeast expression systems
WO2009155724A3 (en) Stable and soluble antibodies inhibiting vegf
WO2009073905A8 (de) Verfahren zur erhöhung der immunreaktivität
WO2008030273A3 (en) Compositions and methods for diagnosis and treatment of type 2 diabetes
WO2011135194A3 (en) Method for diagnosing risk of type 1 diabetes and for preventing onset of type 1 diabetes
WO2006116181A3 (en) Regulatory t cell mediator proteins and uses thereof
WO2007141280A3 (en) Proteins
WO2010143871A3 (ko) 재설계 유전자 회로를 이용한 다양한 효소 활성의 탐색 및 정량 방법
WO2008021976A3 (en) Anti-interferon alpha monoclonal antibodies and methods for use
WO2008112903A3 (en) Genetic alterations on chromosome 16 and methods of use thereof for the diagnosis and treatment of type 1 diabetes
WO2005071067A3 (en) Non-animal origin stabilizers and processes for producing the same
WO2007101063A3 (en) Treatment of development-related disorders
WO2009028418A1 (ja) シクロスポリンａ結合タンパク質
WO2007087263A3 (en) Human zip1, zinc and citrate for prostate cancer screening
WO2009048658A3 (en) Optimized dengue virus entry inhibitory peptide (dn81)
WO2008100290A3 (en) Recombinant rhinovirus vectors
ATE554388T1 (de) Verfahren und immunabsorbentien zur spezifischen detektion und absorption zöliakie- und dermatitis herpetiformis assoziierter antikörper
WO2009069132A3 (en) Novel reverse transcriptase inhibitors
WO2018075633A3 (en) Compositions and methods for detecting or quantifying hepatitis c virus
WO2010079076A3 (de) Autosomal dominante polyzystische nierenerkrankung (adpkd)

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08828474

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2009530084

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2008828474

Country of ref document: EP